SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Lidak Pharm. [LDAKA] -- Ignore unavailable to you. Want to Upgrade?

To: telebob who wrote (799)1/5/1998 1:17:00 PM
From: Henry Niman  Read Replies (1) | Respond to of 1115
 
telebob, My recollection (and I haven't found the press release) was that both Lidakol and the placebo "worked", significantly reducing the time to heal the sores, compared to historical untreated controls (but both worked equally well, so the difference between Lidakol & Placebo #1 were not statistically different, with Placebo #1 being slightly better than Lidakol, and both working much better than untreated lesions of "historical" patients).


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News